In summary, the development of 89Zr-DFO-anti-PD-L1-mAb tracers with an optimal CAR, such as a CAR of 1.4 to 2.0, for imaging PD-L1 expression in tumors may improve the specific activity of the tracers, tumor accumulation of the tracers, and contrast of tumor imaging. This evidence concerns the gene CD274 and neoplasm.